Latest Developments in Altimmune's Class Action Lawsuit
Investors who have suffered losses from Altimmune, Inc. (NASDAQ: ALT) are being encouraged to consider their legal options following the announcement of a class action lawsuit. This legal action was initiated by the law firm Bragar Eagel & Squire, P.C., which is known for its focus on shareholder rights. The firm’s litigation partner, Brandon Walker, is urging affected investors to reach out for support regarding their claims.
Background on the Class Action Lawsuit
The lawsuit, which has been filed in the United States District Court, addresses concerns related to misleading statements made by Altimmune during a specified time frame. Investors who purchased securities from Altimmune between certain dates are eligible to participate in this class action. This timeline is significant as it encapsulates key events linked to the company’s performance in the market.
Implications for Investors
Those who acquired shares within this timeframe, particularly between August 10, 2023, and June 25, 2025, might have grounds to seek restitution for any financial losses experienced. According to the firm, investors should act swiftly as there are deadlines imposed for joining as lead plaintiffs in the lawsuit.
Understanding the Trial and Its Findings
The crux of the suit centers on Altimmune's announcement regarding the results of its IMPACT Phase 2b MASH trial for Pemvidutide. While there were initial positive expectations, reports indicated that the results did not meet industry standards for statistical significance concerning the primary endpoint of fibrosis reduction. Critics have pointed out that the trial's findings were far from the optimistic forecasts projected by the company prior to the announcement.
Market Response
This news was not well-received in the market. Following the press release, shares of Altimmune witnessed a dramatic drop, plummeting from $7.71 to $3.61 in just one day—a staggering decline of over 53%. This sharp loss further intensified concerns among shareholders, prompting the pursuit of legal options to seek redress.
How to Get Involved
If you believe you fall under the umbrella of affected investors, the law firm recommends that you reach out for a confidential discussion regarding your situation. The team at Bragar Eagel & Squire, P.C. is ready to assist people who purchased Altimmune shares and have suffered losses due to the company’s actions. They encourage potential plaintiffs to understand their rights and explore the legal avenues available to them.
Contact Information
Interested investors can contact Brandon Walker or Marion Passmore at (212) 355-4648 for further guidance. Additionally, you can email investigations@bespc.com to initiate a conversation about how to take part in the lawsuit.
About Bragar Eagel & Squire, P.C.
This law firm has established a prominent reputation across the United States for advocating for individual and institutional investors. With offices in multiple states, they offer comprehensive services related to various types of complex litigation, including securities and derivative actions. They have successfully represented clients in both state and federal courts.
Frequently Asked Questions
What is the class action lawsuit against Altimmune about?
The class action lawsuit addresses misleading statements made by Altimmune regarding the outcomes of its clinical trials and the consequent financial losses incurred by shareholders.
How can investors participate in the lawsuit?
Investors can participate by contacting Bragar Eagel & Squire, P.C. to discuss their legal rights and options available to them.
What are the key dates for the lawsuit?
Investors who were involved between August 10, 2023, and June 25, 2025, should be aware of the deadline to apply as a lead plaintiff, which is set by the court.
What were the market reactions following the announcement?
The announcement resulted in a significant drop in Altimmune's stock price, reflecting widespread concern and negative sentiment among investors.
Who should investors contact for more information?
Investors should reach out directly to the attorneys at Bragar Eagel & Squire, P.C. for guidance and support regarding their situation.
